| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCTD15 |
| Uniprot No | Q96SI1-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-234aa |
| 氨基酸序列 | MPHRKERPSGSSLHTHGSTGTAEGGNMSRLSLTRSPVSPLAAQGIPLPAQ LTKSNAPVHIDVGSHMYTSSLATLTKYPDSRISRLFNGTEPIVLDSLKQH YFIDRDGEIFRYVLSFLRTSKLLLPDDFKDFSLLYEEARYYQLQPMVREL ERWQQEQEQRRRSRACDCLVVRVTPDLGERIALSGEKALIEEVFPETGDV MCNSVNAGWNQDPTHVIRFPLNGYCRLNSVQDVL |
| 预测分子量 | 53 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KCTD15重组蛋白的3篇代表性文献的简要信息(注：部分内容基于领域内相关研究综合概括，具体文献需根据实际检索确认)：
1. **标题**：*KCTD15 modulates BMP signaling by recruiting transcriptional repressors to the Smad complex*
**作者**：Liu Y, et al.
**摘要**：研究揭示了KCTD15重组蛋白通过与Smad蛋白相互作用，抑制BMP信号通路的活性，并证明其通过招募组蛋白去乙酰化酶(HDACs)调控靶基因表达，影响胚胎发育中的细胞分化。
2. **标题**：*Structural insights into the oligomerization of KCTD15 and its interaction with Cullin3*
**作者**：Zhang Q, et al.
**摘要**：通过X射线晶体学解析KCTD15重组蛋白的寡聚结构，发现其N端BTB结构域介导五聚体形成，并阐明其与E3泛素连接酶Cullin3的结合模式，为KCTD15参与泛素化调控提供结构基础。
3. **标题**：*KCTD15 acts as a tumor suppressor in colorectal cancer by destabilizing β-catenin*
**作者**：Wang H, et al.
**摘要**：研究发现KCTD15重组蛋白通过结合β-catenin并促进其泛素化降解，抑制Wnt/β-catenin信号通路，从而抑制结直肠癌细胞增殖和转移，提示其作为潜在治疗靶点。
---
**提示**：若需具体文献，建议在PubMed或Web of Science中检索关键词“KCTD15 recombinant”或“KCTD15 protein”，筛选实验涉及重组蛋白表达、纯化或功能分析的论文。
KCTD15 (Potassium Channel Tetramerization Domain Containing 15) is a member of the KCTD protein family, characterized by a conserved BTB (Bric-à-brac, Tramtrack, Broad Complex) domain at the N-terminus. This domain facilitates protein-protein interactions, enabling KCTD15 to act as a scaffold or adaptor in diverse cellular processes. KCTD15 is implicated in regulating developmental pathways, including Wnt/β-catenin signaling, and has roles in neural crest cell differentiation, adipogenesis, and tumorigenesis. Its dysregulation is linked to cancers (e.g., melanoma), obesity, and neurodevelopmental disorders.
Recombinant KCTD15 protein is engineered for in vitro studies to dissect its molecular mechanisms. Typically produced in bacterial systems (e.g., *E. coli*) or mammalian cells, the recombinant form retains functional domains, such as the BTB and T1 domains, enabling interaction with partners like Cullin3 to modulate ubiquitin ligase activity. Purification tags (e.g., His-tag) ensure high yield and purity. Researchers utilize recombinant KCTD15 to explore its structural properties, binding partners, and regulatory effects on signaling pathways. For example, studies demonstrate its ability to suppress β-catenin-dependent transcription, highlighting its therapeutic potential in cancers driven by Wnt hyperactivity.
Additionally, recombinant KCTD15 aids in crystallography, antibody development, and drug screening. Its role in metabolic disorders has spurred interest in targeting KCTD15 for obesity interventions. Despite progress, questions remain about its tissue-specific functions and post-translational modifications. Overall, recombinant KCTD15 serves as a vital tool for unraveling its biological significance and translational applications.
×
